|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||50.26 - 50.82|
|52-week range||50.26 - 50.82|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||38.30|
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.
Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.
NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.